Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma-Reference-Cited by-同舟云学术

Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma

Published:2023-04-25 Issue:5 Volume:17 Page:1289-1299
ISSN:1936-0533
Container-title:Hepatology International
language:en
Short-container-title:Hepatol Int

Author:

Saeki Issei,Suehiro Yutaka,Yamauchi Yurika,Hoshida Tomomi,Tanabe Norikazu,Oono Takashi,Kawamoto Daiki,Nishimura Tatsuro,Matsumoto Toshihiko,Ishikawa Tsuyoshi,Shimokawa Mototsugu,Tamori Akihiro,Kawada Norifumi,Tamai Yasuyuki,Iwasa Motoh,Nakagawa Hayato,Nagano Hiroaki,Takami Taro,Yamasaki Takahiro^ORCID

Funder

Japan Society for the Promotion of Science

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Hepatology

Link

https://link.springer.com/content/pdf/10.1007/s12072-023-10488-y.pdf

Reference33 articles.

1. Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol. 2022;763:681–693

2. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905